Pitt Street Research | Stock research
Island-Pharmaceuticals-logo.png

Island Pharmaceuticals

Island Pharmaceuticals (ASX: ILA) is an ASX-listed biotech company developing its flagship drug ISLA-101 against mosquito diseases. After years of research and successful clinical data, the company has commenced a Phase II study of ISLA-101 for Dengue fever. Results from the first cohort are expected prior to Christmas, with full results in the first half of CY25.

Island Pharmaceuticals (ASX:ILA)

 

Island Pharmaceuticals (ASX: ILA) is an ASX-listed biotech company developing its flagship drug ISLA-101 against mosquito diseases. After years of research and successful clinical data, the company has commenced a Phase II study of ISLA-101 for Dengue fever. Results from the first cohort are expected prior to Christmas, with full results in the first half of CY25.

On 1 October 2024, Island Pharmaceuticals (ASX:ILA) Executive Chairman Dr. Paul MacLeman spoke at the Pitt Street Research Life Sciences Conference 2024.